Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.50
Bid: 3.00
Ask: 4.00
Change: -0.40 (-10.26%)
Spread: 1.00 (33.333%)
Open: 3.90
High: 0.00
Low: 0.00
Prev. Close: 3.90
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
4 Aug 2022 12:33

Proteome Sciences shares rise 10% after swing to interim profit

(Alliance News) - Proteome Sciences PLC on Thursday said it swung to an interim profit in the first half of 2022 on the strength of its TMT reagents.

Read more
3 Aug 2022 15:57

TRADING UPDATES: Ensilica expects annual profit ahead of expectations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
3 Aug 2022 15:33

Proteome reaches milestone in launch of proteomics service

(Sharecast News) - Proteome Sciences has completed its next milestone towards the launch of 'single cell proteomics' services, it announced on Wednesday, dubbed 'SysQuant SCP'.

Read more
16 May 2022 16:20

TRADING UPDATES: Proteome set for profit rise; Kromek expects loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
16 May 2022 13:35

Proteome Sciences maintains strong order book

(Sharecast News) - Proteome Sciences said in an update on Monday that it had maintained a strong order book after recording a small profit in 2021.

Read more
12 May 2022 11:14

IN BRIEF: Proteome Sciences secures contract with US academic group

Proteome Sciences PLC - Drug development services provider - Secures a contract from major US academic group to evaluate changes on the proteome and phospho-proteome of tissue and blood samples taken from people with and without a neurodegenerative disease. The contract's value exceeds GBP500,000. Proteome refers to entire set of proteins in a cell or organism.

Read more
12 May 2022 10:47

AIM WINNERS & LOSERS: Arc Minerals "turning point"; Titon posts loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
22 Apr 2022 12:01

DIRECTOR DEALINGS: Departing D4T4 co-founder sells GBP900,000 worth

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Thursday and Friday and not separately reported by Alliance News:

Read more
31 Mar 2022 13:04

TRADING UPDATES: Impellam and Maintel in profit; Curtis Banks prospers

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:23

IN BRIEF: Proteome Sciences amends GBP1 million loan with Vulpes

Proteome Sciences PLC - drug development services provider - Amends GBP1 million loan with Vulpes Investment Management Private Ltd, which was signed in the summer of 2018. Accrued interest now repayable on June 30, 2023, extended from May 1, 2022. Notes GBP700,000 is currently drawn on facility.

Read more
29 Mar 2022 15:01

UK earnings, trading statements calendar - next 7 days

Wednesday 30 March 
Anglo Pacific Group PLCFull Year Results
Bank of Cyprus Holdings PLCFull Year Results
Bowleven PLCHalf Year Results
Canadian Overseas Petroleum LtdFull Year Results
Ebiquity PLCFull Year Results
Equals Group PLCFull Year Results
Gulf Keystone Petroleum LtdFull Year Results
Inspired PLCFull Year Results
Keywords Studios PLCFull Year Results
Michelmersh Brick Holdings PLCFull Year Results
Shepherd Neame LtdHalf Year Results
Team17 Group PLCFull Year Results
Thursday 31 March 
Eleco PLCFull Year Results
BBGI Global Infrastrcture SAFull Year Results
Chesnara PLCFull Year Results
Gattaca PLCHalf Year Results
Hostelworld Group PLCFull Year Results
James Halstead PLCHalf Year Results
Mears Group PLCFull Year Results
Record PLCFull Year Results
RTW Venture Fund LtdFull Year Results
S4 Capital PLCFull Year Results
Sportech PLCFull Year Results
Proteome Sciences PLCFull Year Results
Provident Financial PLCFull Year Results
Friday 1 April 
HydrogenOne Capital Growth PLCFull Year Results
Renew Holdings PLCTrading Statement
Medica Group PLCFull Year Results
Monday 4 April 
CentralNic Group PLCFull Year Results
Elixirr International PLCFull Year Results
Xpediator PLCFull Year Results
Tuesday 5 April 
DP Eurasia NVFull Year Results
Homeserve PLCTrading Statement
Moonpig Group PLCTrading Statement
Next Fifteen Communications Group PLCFull Year Results
Quixant PLCFull Year Results
SourceBio International PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
3 Feb 2022 22:31

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

Read more
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 10:45

Proteome Sciences shares climb on GBP1 million contract win

Proteome Sciences shares climb on GBP1 million contract win

Read more
20 Dec 2021 10:08

Proteome Sciences secures $1m contract with pharmaceutical major

(Sharecast News) - Proteomics and biomarker research firm Proteome Sciences has secured a contract valued at more than £1.0m from an unnamed major pharmaceutical company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.